Results 121 to 130 of about 531,619 (367)

Pregnancy-associated cardiac dysfunction and the regulatory role of microRNAs. [PDF]

, 2020
Many crucial cardiovascular adaptations occur in the body during pregnancy to ensure successful gestation. Maladaptation of the cardiovascular system during pregnancy can lead to complications that promote cardiac dysfunction and may lead to heart ...
Aryan, Laila, Eghbali, Mansoureh, Medzikovic, Lejla, Umar, Soban   +3 more
core  

A review of the molecular mechanisms underlying the development and progression of cardiac remodeling [PDF]

, 2017
Pathological molecular mechanisms involved in myocardial remodeling contribute to alter the existing structure of the heart, leading to cardiac dysfunction.
Angelini, Francesco, Bordin, Antonella, Carrizzo, Albino, Chimenti, Isotta, DE FALCO, Elena, Forte, Maurizio, Frati, Giacomo, Nocella, Cristina, Pagano, Francesca, Palmerio, Silvia, Schiavon, Sonia, Schirone, Leonardo, Sciarretta, Sebastiano, Valenti, Valentina, Vecchione, Carmine, Yee, Derek   +15 more
core   +3 more sources

Pathogenesis of ventricular hypertrophy

Journal of the American College of Cardiology, 1985
Growth of the vertebrate heart during embryonic and fetal life is characterized by hyperplasia of myocardial cells. Shortly after birth, myocardial cells lose the capability of dividing, and further growth of the heart is due to myocardial cell hypertrophy and nonmuscle cell hyperplasia.
openaire   +3 more sources

Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development

Advanced Science, EarlyView.
Aided by FABP5, abnormally elevated asprosin in hepatocytes enters the nucleus, targets and inhibits PPARα binding to the CPT1A promoter, thereby suppressing FAO. Circulating asprosin exacerbates insulin resistance, collectively driving MASLD progression.
Yuan‐Yuan Yu, Min Feng, Yi Chen, Hong‐Lin Jia, Qi Zhang, Ming Tong, Yan‐Xi Li, Yu Zhao, Xin‐Xin Liu, Shi‐Feng Cao, Zheng‐kai Wang, Hou‐wei Li, Xue Liu, Yan Zhang   +13 more
wiley   +1 more source

Characterization of Left Ventricular Hypertrophy via Fractional Derivatives [PDF]

arXiv, 2017
In this paper, we have used the concepts of the fractional derivative of rough curves to characterize ECG of LVH patients and compared the results with normal ECGs. In mathematical language, an ECG is a rough curve having Q, R, S points as non-differentiable points where classical derivatives do not exist but fractional derivatives exist.
arxiv  

Community level evaluation of adenoid hypertrophy on the basis of symptom scoring and its X-ray correlation

Journal of Family Medicine and Primary Care, 2016
Introduction: One of the major causes of pediatric morbidity today at the community level is infection involving the ear, nose, and throat. Maximum of these patients respond well initially on general regular medications, but then recurrent complaints are
Yogita Dixit, Prem Siddharth Tripathi
doaj   +1 more source

Eosinophils‐Induced Lumican Secretion by Synovial Fibroblasts Alleviates Cartilage Degradation via the TGF‐β Pathway Mediated by Anxa1 Binding

Advanced Science, EarlyView.
Eosinophils play a crucial role in the progression of temporomandibular joint osteoarthritis (TMJOA). This study demonstrates that eosinophils, induced by OVA/IL‐5, promote Lumican secretion in the synovium, which binds to Annexin A1 in chondrocytes, inhibiting transforming growth factor β2 and Smad2/3 phosphorylation.
Wenqian Chen, Yuwei Zhou, Wenxiu Yuan, Yanjing Ou, Hanyu Lin, Kaixun He, Xueshen Qian, Huachen Chen, Chengchaozi Wang, Jie Lu, Weiping Chen, Dexiong Li, Jiang Chen   +12 more
wiley   +1 more source

Human Relaxin‐2 Fusion Protein Treatment Prevents and Reverses Isoproterenol‐Induced Hypertrophy and Fibrosis in Mouse Heart

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Heart failure is one of the leading causes of death in Western countries, and there is a need for new therapeutic approaches. Relaxin‐2 is a peptide hormone that mediates pleiotropic cardiovascular effects, including antifibrotic, angiogenic ...
Junhui Sun, Weidong Hao, Natasha Fillmore, Hanley Ma, Danielle Springer, Zu‐Xi Yu, Agnieszka Sadowska, Andrew Garcia, Ruoyan Chen, Vanessa Muniz‐Medina, Kim Rosenthal, Jia Lin, Denison Kuruvilla, Jane Osbourn, Sotirios K. Karathanasis, Jill Walker, Elizabeth Murphy   +16 more
doaj   +1 more source

TREATMENT OF PROSTATIC HYPERTROPHY. [PDF]

JAMA: The Journal of the American Medical Association, 1901
Prostatic hypertrophy causes misery to a large proportion of men in advanced life, and results in such serious consequences that we must welcome every effort that is made to our means of curing or relieving its unfortunate victims. Fortunately much has been accomplished in this direction of late, and the author wishes to take this opportunity to ...
openaire   +2 more sources

Cardiomyocyte‐Enriched USP20 Ameliorates Pathological Cardiac Hypertrophy by Targeting STAT3 Deubiquitination

Advanced Science, EarlyView.
Cardiomyocyte‐enriched USP20 regulates the K63‐linked ubiquitination of STAT3, and the cardiomyocyte‐specific USP20‐STAT3‐CARM1 axis exerts a protective role in cardiac hypertrophy. Targeting USP20 through cardiac‐specific gene therapy presents a promising strategy for the treatment of cardiac hypertrophy.
Lingfeng Zhong, Shanshan Dai, Fan Yu, Guo‐Ping Shi, Qinyan Gong, Yucong Zhang, Jingsi Duan, Zhengyin Lou, Zhixuan Tang, Fuzhe Gong, Derong Chen, Liya Hou, Xinyang Hu, Jinghai Chen, Jian'an Wang, Deling Yin   +15 more
wiley   +1 more source